Menu
Search
|

Menu

Close
X

Agenus Inc AGEN.OQ (NASDAQ Stock Exchange Capital Market)

2.24 USD
-- (--)
As of Jul 19
chart
Previous Close 2.24
Open --
Volume --
3m Avg Volume 369,477
Today’s High --
Today’s Low --
52 Week High 6.19
52 Week Low 2.05
Shares Outstanding (mil) 87.00
Market Capitalization (mil) 409.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
43
FY16
23
FY15
25
EPS (USD)
FY18
-0.528
FY17
-1.220
FY16
-1.461
FY15
-1.152
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
9.95
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.84
LT Debt to Equity (MRQ)
vs sector
--
12.51
Return on Investment (TTM)
vs sector
-75.39
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Garo Armen
Chairman of the Board, Chief Executive Officer, Founder, Since 1994
Salary: $575,000.00
Bonus: $485,000.00
Christine Klaskin
Principal Accounting Officer, Since 2018
Salary: $250,000.00
Bonus: $102,000.00
Evan Kearns
Vice President, General Counsel, Secretary, Since 2018
Salary: --
Bonus: --
Karen Valentine
General Counsel, Chief Legal Officer, Since 2015
Salary: $340,000.00
Bonus: $210,000.00
Ozer Baysal
Chief Commercial Officer, Head of HR, Since 2017
Salary: $209,000.00
Bonus: $95,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3 Forbes Rd
LEXINGTON   MA   02421-7305

Phone: +1781.6744410

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

SPONSORED STORIES